BIIB Biogen Inc. - Fundamental Analysis
NEUTRAL
BIIB Stock | Fundamental Analysis & Investment Insights
NASDAQ
•
Healthcare
•
Drug Manufacturers - General
Current Price
$177.82
Analyst Target
$182.07
+2.4% Upside
52W High
$185.17
52W Low
$110.04
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
72%
Analysis Accuracy
The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating borderline financial health, while the Altman Z-Score is astronomically high at 52.6 billion, suggesting no distress risk. The stock trades near its Graham Number ($175.03) at $177.82, implying fair value for a defensive investor, though growth expectations are muted. Despite strong profitability metrics and a solid balance sheet, recent earnings declines, weak insider sentiment, and lackluster long-term price performance temper optimism. Analysts recommend a 'buy' with a target of $182.07, slightly above current levels, supporting modest upside.
Key Strengths
Exceptionally high Altman Z-Score (>52 billion) indicates virtually no bankruptcy risk
Strong profitability with gross margin of 76.56%, operating margin of 30.72%, and solid ROE of 9.31%
Healthy liquidity position with current ratio of 2.72 and quick ratio of 1.77
Low debt/equity ratio of 0.36, well below sector average of 1.06
Forward P/E of 11.69 is significantly below sector average of 36.60, suggesting valuation discount
Key Risks
Weak Piotroski F-Score of 4/9 signals deteriorating financial fundamentals
Recent YoY EPS growth of -22.3% and Q/Q EPS drop of -42.0% indicate sharp earnings deterioration
Negative long-term price performance: -34.8% over 3 years and -26.8% over 5 years
Insider activity is bearish with net selling in the last 6 months
Technical trend score of 10/100 reflects strong bearish momentum in the short term
AI Fair Value Estimate
Based on comprehensive analysis
$175.03
-1.6% below current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare BIIB against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations